Company: SUPN
Filing Date: 2025-06-16
Form Type: SC TO-C
Source: 0001104659-25-059956
Chunk: 4

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-06-16
Form: SC TO-C
Chunk 4
---
NS) diseases.

Our diverse neuroscience portfolio includes approved
treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based
therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS
product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.

Supernus was incorporated in Delaware, commenced
operations in 2005, became publicly traded in 2012, and its common stock is listed on the NASDAQ Stock Exchange under the ticker symbol
SUPN.

Item 12. Exhibits.

| Exhibit No. |     | Description                                                         |
| (a)(5)(C)   |     | Transcript of Supernus Inc. Investor Presentation on June 16, 2025. |
| (a)(5)(D)   |     | Note to Sage Employees sent on June 16, 2025.                       |